Loading...
Schwabe Pharma Asia Pacific
to top

Schwabe's History
Our Tradition

Phytopharmaceutical Product
Homoeopathic Medicines

1866

Dr. Willmar Schwabe founds the company in Leipzig.
Ginkgo Biloba Drug
Herbal Medicinal Products

1872

Dr. Schwabe's "Pharmacopoeia Homoeopathica Polyglottica" is published in several languages.
Tebonin Forte
phytopharmaceutical product

1878

Schwabe's first phytopharmaceutical product, "Schwabe's hamamelis ointment" today's Hametum® is launched.
Medication for mental health
Promotes blood circulation medication

1898

The first company abroad is founded in Amsterdam, the Netherlands.
EGb 761
diminished mental performance

1917

Pharmacist Dr. Willmar Schwabe II takes over the company management.
Vitango
Traditional Herbal Medicinal

1926

Schwabe Pharmaceuticals moves to new premises in Leipzig, Germany
Relief of the Mental and Physical Symptoms of Stress
Mental and Physical Elements of Tension

1935

The company management passes to Dr. Willmar Schwabe III, physician and pharmacist, and Dr. Wolfgang Schwabe, pharmacist and business executive.
Non-sedative and Non-addictive
Crataegutt®

1943

Crataegutt®, a phytomedicine for heart failure is launched.
Standardized Rhodiola rosea Extract
Schwabe Pharmaceuticals

1946

Schwabe Pharmaceuticals starts its operations in the new premises in Karlsruhe-Durlach.
Kaloba
homoeopathic medicines

1961

The Deutsche Homöopathie-Union (German Homoeopathic Union, DHU) company is founded, manufacturing and distributing homoeopathic medicines, while the Schwabe parent company concentrates all its Research and Development activities on allopathic phytomedicines.
Tebonin
Tebonin Forte

1965

Tebonin®, the first Ginkgo biloba drug, is launched in Germany.
Venoplant
Venoplant

1975

Venoplant® retard is introduced to the German market.
Non-drowsy Medication for Cough and Cold Symptoms
Biochemist Dr. Klaus-Peter Schwabe

1976

Biochemist Dr. Klaus-Peter Schwabe becomes managing director.
Medicine for Coughs
Dr. Wolf-Dietrich Schwabe

1977

Business executive Dr. Wolf-Dietrich Schwabe becomes managing director.

1980

The Schwabe group enters the Mexican market via the company Farmasa.
Immune System Against the Infection
Tebonin® forte

1982

Tebonin® forte is launched.
decreasing heart performance
Crataegutt® novo

1983

Crataegutt® novo is introduced in Germany as a treatment for decreasing heart performance.
Pelargonium Sidoides
Spitzner Pharmaceuticals

1985

In Germany, Spitzner Pharmaceuticals is acquired.
Men Urinary Flow Medication
Ginkgo plantations

1985 - 1991

The company sets up its own Ginkgo plantations in France and United States.

Further companies are purchased in Italy, Switzerland, Spain, Germany and the US.
herbal medicine
Schwabe Pharma AG

1992

The Schwabe Pharma AG is founded in Switzerland.

Schwabe enters the US herbal medicine market via Nature’s Way, Inc…
Prostakan
Dr. Willmar Schwabe India Pvt. Lt

1994

In India Dr. Willmar Schwabe India Pvt. Ltd is founded.

In Austria the Austroplant Arzneimittel Gmbh starts business.
Saw Palmetto and Stinging Nettle
Schwabe-Wenex International

1996 - 1999

Schwabe-Wenex International starts operations in Hongkong.

Schwabe’s representative office in Moscow, Russia is founded.
Relief Blood Flow in Legs
Relief Blood Flow in Legs

2000 - 2003

Schwabe enters the Czech, Slovakian and Hungarian market via own subsidiaries of ASI.
Prostate Health Singapore
Schwabe Pharma Asia Pacific Pte. Ltd

2005

In Singapore, Schwabe Pharma Asia Pacific Pte. Ltd. starts operations.
Prostakan
Abkit Inc. USA

2006

Abkit Inc. USA is purchased.
legs Veins and Capillaries Medication
Enzymatic Therapy

2008

Schwabe acquires MH Pharma UK.

Enzymatic Therapy Inc is purchased.
Legs Veins Medication
Dr. Peithner Holding GmbH

2009

Schwabe acquires Dr. Peithner Holding GmbH, Vienna, Austria
Venosan
Lasea®

2010

In September 2010 Lasea® is launched in the German market.
Phytopharmaceutical Product
Olaf Schwabe

2016

Olaf Schwabe, fifth-generation CEO

Since 1 May 2016, Olaf Schwabe has been the head of the Schwabe Group, representing the fifth generation of the family. As the chief executive officer, he is one of the five-member Group Executive Team which is responsible for business operations at the Schwabe Group and defines their global strategy.

By late 2016, the Schwabe Group had achieved sales of €900 million. The Schwabe Group currently employs around 3,600 people worldwide.